Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

RIGL

Rigel Pharmaceuticals

Mar 11 • 04:00PM ET

19.49

Dollar change -0.04
Percentage change -0.20	%

Healthcare • Biotechnology • USA • NASD

Peers: GILD INCY NVAX VKTX ARWR ACAD ENTA KURA AMRN ANAB

| Held by: VTI IWM VXF IWO IBB VTWO IWC IWN SMIZ IDNA

Scroll to Statements

Index	RUT	P/E	20.06	EPS (ttm)	0.97	Insider Own	2.71%	Shs Outstand	17.71M	Perf Week	-11.73%
Market Cap	348.15M	Forward P/E	10.89	EPS next Y	1.79	Insider Trans	-3.94%	Shs Float	17.38M	Perf Month	-11.17%
Income	17.48M	PEG	0.59	EPS next Q	0.09	Inst Own	68.22%	Short Float	7.76%	Perf Quarter	-25.12%
Sales	179.28M	P/S	1.94	EPS this Y	25.59%	Inst Trans	1.83%	Short Ratio	4.95	Perf Half Y	46.32%
Book/sh	0.19	P/B	104.98	EPS next Y	43.96%	ROA	5.73%	Short Interest	1.35M	Perf Year	27.39%
Cash/sh	4.33	P/C	4.50	EPS next 5Y	33.74%	ROE	-	52W Range	7.48 - 29.82	Perf YTD	15.87%
Dividend Est.	-	P/FCF	11.08	EPS past 5Y	-	ROI	31.39%	52W High	-34.64%	Beta	1.28
Dividend TTM	-	Quick Ratio	1.98	Sales past 5Y	30.35%	Gross Margin	89.60%	52W Low	160.41%	ATR (14)	1.54
Dividend Ex-Date	-	Current Ratio	2.13	EPS Y/Y TTM	168.50%	Oper. Margin	13.49%	RSI (14)	42.48	Volatility	8.98% 6.83%
Employees	164	Debt/Eq	18.23	Sales Y/Y TTM	53.38%	Profit Margin	9.75%	Recom	2.20	Target Price	35.80
Option/Short	Yes / Yes	LT Debt/Eq	15.93	EPS Q/Q	1789.34%	Payout	0.00%	Rel Volume	1.06	Prev Close	19.53
Sales Surprise	14.96%	EPS Surprise	77.46%	Sales Q/Q	60.92%	Earnings	Mar 04 AMC	Avg Volume	272.32K	Price	19.49
SMA20	-7.28%	SMA50	-3.40%	SMA200	23.13%	Trades		Volume	288,194	Change	-0.20%

Date	Action	Analyst	Rating Change	Price Target Change
Apr-03-23	Resumed	Piper Sandler	Neutral	$2
Jun-09-22	Downgrade	Citigroup	Buy → Neutral
Jun-08-22	Downgrade	Piper Sandler	Overweight → Neutral	$7 → $1
Jun-08-22	Downgrade	Cantor Fitzgerald	Overweight → Neutral	$6 → $1
Mar-23-22	Initiated	B. Riley Securities	Neutral	$4
Nov-09-20	Downgrade	JP Morgan	Overweight → Neutral
Nov-15-19	Resumed	Cantor Fitzgerald	Overweight	$7 → $5
Sep-26-19	Resumed	JP Morgan	Overweight	$7
Mar-01-19	Reiterated	Cantor Fitzgerald	Overweight	$9 → $7
Aug-27-18	Initiated	Citigroup	Buy	$8.50
May-02-18	Reiterated	Cantor Fitzgerald	Overweight	$6 → $9
Dec-21-17	Resumed	Piper Jaffray	Overweight	$6
Dec-15-17	Initiated	Cantor Fitzgerald	Overweight	$6
Nov-06-17	Resumed	H.C. Wainwright	Buy	$7
Mar-09-17	Reiterated	H.C. Wainwright	Buy	$6 → $5
Aug-31-16	Reiterated	H.C. Wainwright	Buy	$6 → $7
Aug-30-16	Reiterated	Piper Jaffray	Overweight	$10 → $11
Jul-13-16	Initiated	H.C. Wainwright	Buy	$6
Jun-13-16	Initiated	Piper Jaffray	Overweight
Apr-22-16	Upgrade	JP Morgan	Neutral → Overweight

Show Previous Ratings

Mar-10-25 08:05AM	Rigel Appoints Mark W. Frohlich, M.D. to Board of Directors (PR Newswire)
Mar-05-25 10:25AM	Q4 2024 Rigel Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents) -8.11%
09:55AM	Wall Street Analysts Believe Rigel (RIGL) Could Rally 44.93%: Here's is How to Trade (Zacks)
02:08AM	Rigel Pharmaceuticals Inc (RIGL) Q4 2024 Earnings Call Highlights: Record Revenue and Strategic ... (GuruFocus.com)
Mar-04-25 05:15PM	Rigel Pharmaceuticals (RIGL) Surpasses Q4 Earnings and Revenue Estimates (Zacks)
04:23PM	Loading…
04:23PM	Rigel: Q4 Earnings Snapshot (Associated Press Finance)
04:01PM	Rigel Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update (PR Newswire)
Mar-03-25 07:14AM	Rigel Pharmaceuticals Inc (RIGL) Q4 2024: Everything You Need To Know Ahead Of Earnings (GuruFocus.com)
Feb-25-25 08:05AM	Rigel Announces Conference Call and Webcast to Report Fourth Quarter and Full Year 2024 Financial Results and Business Update (PR Newswire)
Feb-03-25 09:55AM	Does Rigel (RIGL) Have the Potential to Rally 40.88% as Wall Street Analysts Expect? (Zacks)
Jan-23-25 07:27AM	Rigel enrols first subject in Phase I sickle cell disease therapy trial (Clinical Trials Arena)
Jan-22-25 08:05AM	Rigel's Fostamatinib Being Studied by National Institute of Health in Patients with Sickle Cell Disease (PR Newswire)
Jan-17-25 09:55AM	Wall Street Analysts Predict a 75.79% Upside in Rigel (RIGL): Here's What You Should Know (Zacks) +16.02%
Jan-15-25 12:00PM	Rigel (RIGL) Upgraded to Buy: Here's Why (Zacks) +7.91%
Jan-13-25 08:05AM	Rigel Provides Business Update and 2025 Outlook (PR Newswire) +5.29%
08:05AM	Loading…
Jan-09-25 08:05AM	Rigel Announces R289 Granted Orphan Drug Designation by the FDA for MDS (PR Newswire)
Jan-08-25 08:05AM	Rigel to Present at the 43rd Annual J.P. Morgan Healthcare Conference (PR Newswire)
Jan-03-25 08:05AM	Rigel Pharmaceuticals, Inc. Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4) (PR Newswire)
Dec-09-24 12:02PM	Rigel Highlights Initial Data from Ongoing Phase 1b Study Evaluating R289 in LR-MDS at the 66th ASH Annual Meeting and Exposition (PR Newswire) -9.00%
Dec-02-24 08:05AM	Rigel Announces R289 Granted Fast Track Designation by the FDA for Lower-Risk MDS (PR Newswire)
Nov-19-24 09:55AM	How Much Upside is Left in Rigel (RIGL)? Wall Street Analysts Think 28.28% (Zacks) +5.15%
Nov-12-24 08:05AM	Rigel to Present at the Jefferies London Healthcare Conference (PR Newswire) +9.10%
Nov-08-24 09:48AM	Q3 2024 Rigel Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents) +42.94%
02:27AM	Rigel Pharmaceuticals Inc (RIGL) Q3 2024 Earnings Call Highlights: Strong Sales Growth and ... (GuruFocus.com)
Nov-07-24 05:15PM	Rigel Pharmaceuticals (RIGL) Q3 Earnings and Revenues Top Estimates (Zacks)
04:09PM	Rigel: Q3 Earnings Snapshot (Associated Press Finance)
04:01PM	Rigel Reports Third Quarter 2024 Financial Results and Provides Business Update (PR Newswire)
Nov-06-24 07:42AM	Rigel Pharmaceuticals Inc (RIGL) Q3 2024 Earnings Report Preview: What To Expect (GuruFocus.com)
Nov-05-24 09:05AM	Rigel Announces Six Poster Presentations at the 66th American Society of Hematology Annual Meeting and Exposition (PR Newswire)
Oct-31-24 08:05AM	Rigel Announces Conference Call and Webcast to Report Third Quarter 2024 Financial Results and Business Update (PR Newswire)
04:35PM	Loading…
Oct-24-24 04:35PM	Rigel Pharmaceuticals Issues Dear Healthcare Provider Letter for GAVRETO (pralsetinib) (PR Newswire)
Oct-16-24 10:00AM	Optime Care Expands Partnership with Rigel Pharmaceuticals to Include Commercial Distribution for TAVALISSE (GlobeNewswire)
Oct-04-24 08:05AM	Rigel Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4) (PR Newswire)
Sep-25-24 04:34AM	Rigel (RIGL) Surges 19.7%: Is This an Indication of Further Gains? (Zacks)
Sep-12-24 08:05AM	Rigel to Present at the 2024 Cantor Global Healthcare Conference (PR Newswire)
Sep-06-24 06:32AM	Rigel enrols first participant in Phase Ib/II AML treatment regimen trial (Clinical Trials Arena)
Sep-05-24 07:30AM	Rigel Announces First Patient Enrolled in Phase 1b/2 Triplet Therapy Trial of REZLIDHIA (olutasidenib) in mIDH1 AML (PR Newswire)
Sep-03-24 08:00AM	Rigel Expands Relationship with Kissei to include REZLIDHIA (olutasidenib) in Japan, the Republic of Korea and Taiwan (PR Newswire)
Aug-29-24 08:05AM	Rigel to Participate in Upcoming September Investor Conferences (PR Newswire) +5.04%
Aug-07-24 11:12AM	Q2 2024 Rigel Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents) +5.79%
Aug-06-24 05:30PM	Rigel Pharmaceuticals (RIGL) Reports Q2 Loss, Tops Revenue Estimates (Zacks) +6.02%
04:25PM	Rigel: Q2 Earnings Snapshot (Associated Press Finance)
04:01PM	Rigel Reports Second Quarter 2024 Financial Results and Provides Business Update (PR Newswire)
Jul-30-24 10:01AM	Rigel Pharmaceuticals (RIGL) Expected to Beat Earnings Estimates: Can the Stock Move Higher? (Zacks)
08:05AM	Rigel Announces Conference Call and Webcast to Report Second Quarter 2024 Financial Results and Business Update (PR Newswire)
Jul-12-24 08:05AM	Rigel Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4) (PR Newswire)
Jun-25-24 08:00AM	Rigel Announces Reverse Stock Split (PR Newswire) -11.87%
Jun-24-24 04:05PM	Rigel Pharmaceuticals Completes Transfer of GAVRETO (pralsetinib) New Drug Application (PR Newswire)
Jun-17-24 09:36AM	Penny Stock Picks: 3 Companies Poised to Graduate to the Big Leagues (InvestorPlace)
Jun-14-24 03:05AM	Rigel Announces Five Presentations at the EHA2024 Hybrid Congress (PR Newswire)
Jun-03-24 08:13AM	Rigel Highlights New Data in Three Poster Presentations at the 2024 ASCO Annual Meeting (PR Newswire)
May-30-24 08:05AM	Rigel to Present at the Jefferies Global Healthcare Conference (PR Newswire)
May-23-24 05:00PM	Rigel Announces Presentations at the Upcoming 2024 ASCO Annual Meeting and EHA2024 Hybrid Congress (PR Newswire)
May-10-24 12:00PM	Rigel (RIGL) Upgraded to Buy: Here's What You Should Know (Zacks)
May-08-24 12:47PM	Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Q1 2024 Earnings Call Transcript (Insider Monkey) -16.61%
03:49AM	Rigel Pharmaceuticals Inc (RIGL) Q1 2024 Earnings Call Transcript Highlights: Strategic Moves ... (GuruFocus.com)
May-07-24 09:00PM	RIGL Stock Earnings: Rigel Pharmaceuticals Misses EPS, Misses Revenue for Q1 2024 (InvestorPlace)
05:50PM	Rigel Pharmaceuticals (RIGL) Reports Q1 Loss, Lags Revenue Estimates (Zacks)
04:47PM	Rigel: Q1 Earnings Snapshot (Associated Press Finance)
04:01PM	Rigel Reports First Quarter 2024 Financial Results and Provides Business Update (PR Newswire)
Apr-30-24 10:01AM	Rigel Pharmaceuticals (RIGL) May Report Negative Earnings: Know the Trend Ahead of Q1 Release (Zacks)
08:05AM	Rigel Announces Conference Call and Webcast to Report First Quarter 2024 Financial Results and Business Update (PR Newswire)
Apr-10-24 04:30PM	Rigel Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4) (PR Newswire)
Apr-04-24 08:05AM	Rigel Announces Publication of Data on REZLIDHIA (Olutasidenib) in Post-Venetoclax Patients with Mutant IDH1 AML in Leukemia & Lymphoma (PR Newswire)
Mar-12-24 08:05AM	Rigel Pharmaceuticals Announces Appointment of Lisa Rojkjaer, M.D. as Chief Medical Officer (PR Newswire)
Mar-07-24 01:50PM	Rigel Pharmaceuticals Inc (RIGL) Reports Growth in 2023 Sales, Despite Net Loss for the Year (GuruFocus.com)
11:59AM	Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Q4 2023 Earnings Call Transcript (Insider Monkey)
Mar-06-24 11:53AM	Q4 2023 Rigel Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents) +5.41%
Mar-05-24 08:51PM	RIGL Stock Earnings: Rigel Pharmaceuticals Beats Revenue for Q4 2023 (InvestorPlace)
05:10PM	Rigel Pharmaceuticals (RIGL) Reports Break-Even Earnings for Q4 (Zacks)
04:01PM	Rigel Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update (PR Newswire)
Feb-27-24 08:05AM	Rigel Announces Conference Call and Webcast to Report Fourth Quarter and Full Year 2023 Financial Results and Business Update (PR Newswire) +5.63%
Feb-22-24 07:50AM	Rigel Pharmaceuticals Acquires U.S. Rights to GAVRETO (PR Newswire) +16.07%
Feb-19-24 08:34AM	Can Rigel Pharmaceuticals (RIGL) Beat Q4 Earnings Estimates? (Zacks)
Jan-10-24 08:00AM	Akoya Biosciences Announces that Garry Nolan, Ph.D., James Allison, Ph.D., and Padmanee Sharma, M.D., Ph.D., Join Newly Created Scientific Advisory Board (GlobeNewswire)
Jan-08-24 08:54AM	Rigel Pharmaceuticals Expects 2023 Net Product Sales To Rise 36% - Quick Facts (RTT News) +7.25%
08:05AM	Rigel Pharmaceuticals Provides Business Update (PR Newswire)
Jan-05-24 04:30PM	Rigel Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4) (PR Newswire) -7.38%
Jan-04-24 08:05AM	Rigel Announces Collaboration with CONNECT to Conduct a Phase 2 Trial of Olutasidenib in Glioma (PR Newswire)
Jan-03-24 10:51AM	Here's Why You Should Bet on Rigel Pharmaceuticals (RIGL) Now (Zacks)
08:05AM	Rigel to Present at the 42nd Annual J.P. Morgan Healthcare Conference (PR Newswire)
Dec-08-23 08:05AM	Rigel Pharmaceuticals and MD Anderson Announce Strategic Alliance to Advance REZLIDHIA (Olutasidenib) in AML and Other Cancers (PR Newswire) +16.23%
Nov-08-23 03:09PM	Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Q3 2023 Earnings Call Transcript (Insider Monkey)
Nov-07-23 05:06PM	Rigel Pharmaceuticals Inc (RIGL) Reports Q3 2023 Financial Results: A Step Towards Financial ... (GuruFocus.com)
04:30PM	Rigel: Q3 Earnings Snapshot (Associated Press Finance)
04:01PM	Rigel Reports Third Quarter 2023 Financial Results and Provides Business Update (PR Newswire)
Nov-06-23 08:05AM	Rigel to Present at the Jefferies London Healthcare Conference (PR Newswire)
Nov-02-23 09:27AM	Rigel Announces Poster Presentations at the 65th American Society of Hematology Annual Meeting and Exposition (PR Newswire)
Oct-31-23 08:05AM	Rigel Announces Conference Call and Webcast to Report Third Quarter 2023 Financial Results and Business Update (PR Newswire)
Oct-11-23 08:05AM	Rigel Announces Presentation at the Upcoming IDWeek 2023 (PR Newswire)
Oct-06-23 04:30PM	Rigel Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4) (PR Newswire)
Sep-20-23 08:05AM	Rigel to Present at the 2023 Cantor Global Healthcare Conference (PR Newswire)
Aug-30-23 08:05AM	Rigel to Participate in Upcoming September Investor Conferences (PR Newswire)
Aug-02-23 10:16AM	Q2 2023 Rigel Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents)
Aug-01-23 05:15PM	Rigel Pharmaceuticals (RIGL) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
04:08PM	Rigel: Q2 Earnings Snapshot (Associated Press Finance)
04:01PM	Rigel Reports Second Quarter 2023 Financial Results and Provides Business Update (PR Newswire)
Jul-27-23 06:06PM	3 Stocks to Buy for Lottery Jackpot Style Returns (InvestorPlace)
Jul-25-23 08:00AM	Rigel Announces Conference Call and Webcast to Report Second Quarter 2023 Financial Results and Business Update (PR Newswire)
Jul-05-23 04:30PM	Rigel Pharmaceuticals, Inc. Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4) (PR Newswire) +5.34%

Rigel Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. It discovers and develops novel, targeted drugs in the therapeutic areas of immunology, oncology and immune oncology. The firm focuses on intracellular signalling pathways and related targets that are critical to disease mechanisms. The company's products include Tavalisse, Fostamatinib and R835. Rigel Pharmaceuticals was founded by Donald G. Payan, James M. Gower, Thomas A. Raffin, Garry P. Nolan and Ronald B. Garren on June 14, 1996 and is headquartered in South San Francisco, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Schorno Dean L	EVP & Chief Financial Officer	Feb 04 '25	Sale	20.92	2,036	42,595	58,969	Feb 06 08:27 PM
Schorno Dean L	EVP & Chief Financial Officer	Feb 05 '25	Sale	21.93	1,734	38,020	57,235	Feb 06 08:27 PM
Santos David A	EVP, Chief Commercial Officer	Feb 04 '25	Sale	20.92	2,125	44,457	53,500	Feb 06 08:27 PM
Santos David A	EVP, Chief Commercial Officer	Feb 05 '25	Sale	21.93	1,796	39,379	51,704	Feb 06 08:27 PM
RODRIGUEZ RAUL R	CEO, President	Feb 04 '25	Sale	20.92	4,952	103,601	243,854	Feb 06 08:27 PM
RODRIGUEZ RAUL R	CEO, President	Feb 05 '25	Sale	21.93	4,400	96,474	239,454	Feb 06 08:27 PM
Furey Raymond J.	EVP, GC, CCO & Corp Sec	Feb 04 '25	Sale	20.92	1,448	30,294	40,169	Feb 06 08:26 PM
Furey Raymond J.	EVP, GC, CCO & Corp Sec	Feb 05 '25	Sale	21.93	1,339	29,359	38,830	Feb 06 08:26 PM
Santos David A	Officer	Feb 05 '25	Proposed Sale	21.93	1,796	39,379		Feb 05 03:58 PM
Schorno Dean L	Officer	Feb 05 '25	Proposed Sale	21.93	1,734	38,020		Feb 05 03:43 PM
Furey Raymond J.	Officer	Feb 05 '25	Proposed Sale	21.93	1,339	29,359		Feb 05 03:41 PM
RODRIGUEZ RAUL R	Officer	Feb 05 '25	Proposed Sale	21.93	4,400	96,474		Feb 05 03:40 PM
Schorno Dean L	Officer	Feb 04 '25	Proposed Sale	20.92	2,036	42,596		Feb 04 04:39 PM
RODRIGUEZ RAUL R	Officer	Feb 04 '25	Proposed Sale	20.92	4,952	103,602		Feb 04 04:30 PM
Furey Raymond J.	Officer	Feb 04 '25	Proposed Sale	20.92	1,448	30,294		Feb 04 04:21 PM
Santos David A	Officer	Feb 04 '25	Proposed Sale	20.92	2,125	44,458		Feb 04 04:20 PM
RODRIGUEZ RAUL R	CEO, President	Jan 24 '25	Option Exercise	21.40	90,000	1,926,000	250,584	Jan 28 08:49 PM
Masuda Esteban	Officer	Jan 24 '25	Proposed Sale	22.14	4,999	110,678		Jan 24 04:38 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

RIGL

Rigel Pharmaceuticals

Upgrade your FINVIZ experience